PR-006 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Frontotemporal Dementia (FTD). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PR-006’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PR-006 is expected to reach an annual total of $3 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PR-006 is under development for the treatment of frontotemporal dementia with GRN mutation, or FTD-GRN. The gene therapy uses non-replicating recombinant adeno-associated virus serotype 9 (AAV9) to deliver codon-optimized DNA encoding wild-type progranulin and is administered intracisternally into the cerebrospinal fluid (CSF). It is developed based on NAV technology platform.
Eli Lilly and Co Overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$28,541.4 million for the fiscal year ended December 2022 (FY2022), an increase of 0.8% over FY2021. The operating profit of the company was US$7,127.3 million in FY2022, compared to an operating profit of US$5,951.9 million in FY2021. The net profit of the company was US$6,244.8 million in FY2022, compared to a net profit of US$5,581.7 million in FY2021.
For a complete picture of PR-006’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.